Genprex, Inc.
GNPX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595248
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
27
- 0 vs. Q1 2026
- Total value $154.95K
Superinvestors holding GNPX
0
- None of the superinvestors held GNPX at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by GNPX insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | Apr 14, 2026 | LONGNECKER BRENT MDirector | SSaleCommon Stock | −8 | $1.23 | −$9.84 | 9.16K | −0.1% | SEC |
| Apr 15, 2026 | Apr 14, 2026 | LONGNECKER BRENT MDirector | SSaleCommon Stock | −10 | $1.23 | −$12.3 | 0 | −100.0% | SEC |
| Apr 24, 2023 | Apr 21, 2023 | Varner John RodneyChairman, President and CEO | PPurchaseCommon Stock | +19K | $1.06 | +$20.14K | 20.8K | +1,055.6% | SEC |
| Apr 24, 2023 | Apr 21, 2023 | VACZY CATHERINE MEVP GC Chief Strategy Officer | PPurchaseCommon Stock | +20K | $1.07 | +$21.4K | 265K | +8.2% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in GNPX at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VANGUARD FIDUCIARY TRUST CO | 78,104 | $40.54K | 0.00% | +78,104 | New |
| HRT FINANCIAL LP | 72,061 | $37K | 0.00% | +72,061 | New |
| GEODE CAPITAL MANAGEMENT, LLC | 60,348 | $31.32K | 0.00% | +26,976+80.8% | Added |
| VANGUARD CAPITAL MANAGEMENT LLC | 36,350 | $18.87K | 0.00% | +30,400+510.9% | Added |
| Engineers Gate Manager LP | 20,885 | $10.84K | 0.00% | +20,885 | New |